Table 2. Pathological characteristics and postoperative data.
| Group 1 | Group 2 | P | |
|---|---|---|---|
| (2019) | (2020) | ||
| n (%): 56 (54) | n (%): 48 (46) | ||
| Pathological diagnosis, n (%) | |||
| Adenocarcinoma | 56 (100) | 46 (96) | 0.304 |
| Medullary carcinoma | 1 (2) | ||
| Neuroendocrine tumor | 1 (2) | ||
| Pathological tumor stage, n (%) | |||
| T1 | 3 (5) | 0 (0) | 0.240 |
| T2 | 6 (10) | 8 (17) | |
| T3 | 34 (62) | 25 (52) | |
| T4 | 13 (23) | 15 (31) | |
| Pathological lymph node stage, n (%) | |||
| N0 | 39 (70) | 21 (44) | 0.004 |
| N1 | 4 (7) | 15 (31) | |
| N2 | 13 (23) | 12 (25) | |
| Pathological stage, n (%) | |||
| Stage 1 | 9 (16) | 5 (10) | 0.005 |
| Stage 2 | 29 (52) | 11 (23) | |
| Stage 3 | 13 (23) | 21 (44) | |
| Stage 4 | 5 (9) | 11 (23) | |
| Liver metastasis, n (%) | |||
| Yes | 4 (7) | 10 (21) | 0.041 |
| No | 52 (93) | 38 (79) | |
| Synchronous tumor, n (%) | |||
| Yes | 4 (7) | 2 (4) | 0.516 |
| No | 52 (93) | 46 (96) | |
| Peritoneal carcinomatosis, n (%) | |||
| Yes | 2 (4) | 1 (2) | 0.651 |
| No | 54 (96) | 47 (98) | |
| Colostomy, n (%) | 21(37) | 22 (46) | 0.390 |